Sort
48,018 grants matching “immunotherapy”
Developmental Funds
$457,709Peter A Jones · University Of Southern California · P30 · FY2014 · CA
Modulating Intratumoral Immune Composition to Enhance Immunotherapy
$457,683Edwin Manuel · Beckman Research Institute/City Of Hope · R21 · FY2024 · CA
An Environmental Chemical Receptor, the AhR, as a Mediator of Multiple Immune Checkpoints in Oral Cancer
$457,675David H Sherr · Boston University Medical Campus · R01 · FY2024 · ES
LILRB modulates tumor microenvironment and promotes tumor progression
$457,636Shu-Hsia Chen · Icahn School Of Medicine At Mount Sinai · R01 · FY2017 · CA
Aak1 to increase infiltration of adoptively transferred cells into solid tumors
$457,635Laura Marie Rogers · Mayo Clinic Rochester · R37 · FY2025 · CA
Aak1 to increase infiltration of adoptively transferred cells into solid tumors
$457,635Laura Marie Rogers · Mayo Clinic Rochester · R37 · FY2023 · CA
Breaking down tumor immune privilege through targeted hypoxia reduction
$457,607Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor
$457,540Sridhar Nimmagadda · Johns Hopkins University · R01 · FY2020 · CA
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor
$457,540Sridhar Nimmagadda · Johns Hopkins University · R01 · FY2021 · CA
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
$457,524Jelani Chinelo Zarif · Johns Hopkins University · R01 · FY2023 · CA
Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy
$457,521Navin Varadarajan · University Of Houston · R01 · FY2014 · CA
Pathogenesis and treatment of sporadic Inclusion Body Myositis in mouse models.
$457,518Thomas E. Lloyd · Johns Hopkins University · R01 · FY2022 · AR
Restoring Immune Tolerance in a Model of Multiple Sclerosis
$457,500Brad E Hoffman · University Of Florida · R01 · FY2023 · AI
Restoring Immune Tolerance in a Model of Multiple Sclerosis
$457,500Brad E Hoffman · University Of Florida · R01 · FY2024 · AI
Clinical implementation of single cell tumor transcriptome analysis
$457,465Aviv Regev · Broad Institute, Inc. · R33 · FY2016 · CA
Understanding the Targeted and Immunomodulatory Properties of Zwitterionic Functional Materials for mRNA Delivery
$457,390Jiang Shaoyi · Cornell University · · FY2024 · MPS
Achieving Therapeutic Antigent-Specific Tolerance in Type 1 Diabetes
$457,376Matthias G. Von Herrath · La Jolla Institute For Immunology · U01 · FY2010 · DK
Targeted immunotherapy of breast cancer with central memory T cells
$457,354Stanley R Riddell · Fred Hutchinson Cancer Research Center · P50 · FY2012 · CA
APOBEC3 Proteins in HIV Restriction
$457,305Reuben S Harris · University Of Minnesota · R37 · FY2020 · AI
Targeting telomerase for melanoma therapeutics
$457,304Emmanuel Skordalakes · Wistar Institute · R01 · FY2019 · CA
Molecular Mechanisms in Gastrointestinal Stromal Tumor
$457,250Ronald P Dematteo · Sloan-Kettering Inst Can Research · R01 · FY2015 · CA
Molecular Mechanisms in Gastrointestinal Stromal Tumor
$457,250Ronald P Dematteo · Sloan-Kettering Inst Can Research · R01 · FY2012 · CA
eRapa for bladder cancer prevention
$457,121Robert Scott Svatek · University Of Texas Hlth Science Center · R01 · FY2021 · CA
Negative regulation of myeloid-derived suppressive cells in cancer
$457,106Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2019 · CA
Decoding tobacco-related oral cancer ecosystem by integrative approach
$457,093Aik Choon Tan · University Of Utah · R01 · FY2023 · DE